Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results
August 09, 2016 16:01 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome
June 07, 2016 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders,...
Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome
May 05, 2016 08:00 ET
|
Zogenix, Inc.
Patient and Caregiver Sleep Quality and Quality of Life Data Reported for First Time New Clinical Data Presented at 14th International Child Neurology Congress on the Use of Low-Dose Fenfluramine...
Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome
January 19, 2016 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...